AUGTYRO Bristol-Myers Squibb Australia Pty Ltd
Product name
AUGTYRO
Accepted date
May-2024
Active ingredients
repotrectinib
Proposed indication
For the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Application type
A (new medicine)
Publication date
May-2024